Immunosuppressants - Baltics | Statista Market Forecast

The Immunosuppressants market in the Baltics is projected to reach a revenue of US$32.00m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 15.55%, resulting in a market volume of US$65.93m by 2029.
In global comparison, United States will generate the most revenue, with an estimated US$35.47bn in 2024.
In the Baltics, the market for immunosuppressants is experiencing a steady growth due to an increasing number of organ transplant procedures.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The Baltics, consisting of Estonia, Latvia, and Lithuania, have seen a steady growth in the Immunosuppressants market in recent years.

Customer preferences: Patients in the Baltics suffering from autoimmune diseases, organ transplants, and other conditions that require immunosuppressants have been increasingly opting for biologic drugs over traditional drugs. Biologics are seen as more effective and have fewer side effects compared to traditional drugs. Patients in the Baltics also prefer to use generic versions of immunosuppressants due to their lower cost.

Trends in the market: The Immunosuppressants market in the Baltics is expected to continue to grow due to the increasing prevalence of autoimmune diseases and organ transplants. The market is also expected to benefit from the increasing use of biologics and generic drugs. The market is expected to see increased competition as more companies enter the market and as more biologics go off-patent.

Local special circumstances: The Baltics have a relatively small population, which limits the size of the Immunosuppressants market. However, the market is expected to benefit from the increasing availability of healthcare services in the region. The region has also seen an increasing number of medical tourists, which has helped to boost the Immunosuppressants market.

Underlying macroeconomic factors: The Immunosuppressants market in the Baltics is influenced by a number of macroeconomic factors. The region has a relatively low GDP per capita, which limits the ability of patients to pay for expensive drugs. However, the region has seen increasing economic growth in recent years, which has helped to boost the Immunosuppressants market. The region also has a well-developed healthcare system, which has helped to support the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.